2024-02-17 02:57:34 ET
Summary
- Steris reported strong growth in their Healthcare Products and Life Sciences segments, driven by procedure volume increases and market share gains.
- The company has raised their full-year organic growth target to 7-8% and adjusted earnings per share are expected to be $8.60 to $8.70.
- The AST business experienced weak growth and the Dental business faced challenges, but overall, Steris maintains a solid balance sheet and strong free cash flow growth.
...
Read the full article on Seeking Alpha
For further details see:
Steris: Strong Healthcare Products Growth Coupled With Weak AST Business